Personalized Prevention of Heart Attacks and Stroke

Abstract

Heart attacks and strokes remain leading causes of morbidity and mortality globally. A one-size-fits-all approach to prevention is increasingly recognized as suboptimal, given the heterogeneity in risk profiles, genetic predispositions, and environmental exposures among individuals. This review synthesizes current evidence on personalized prevention strategies for cardiovascular and cerebrovascular events, emphasizing risk stratification, biomarker-guided therapy, and integration of genomics with clinical decision-making. We highlight the clinical relevance of individualized approaches, discuss recent advances, and examine guideline-based recommendations for the implementation of precision medicine in cardiovascular prevention.

Introduction

Cardiovascular diseases (CVD), particularly myocardial infarction (MI) and ischemic stroke, continue to impose a significant burden on healthcare systems worldwide. While traditional prevention strategies have successfully reduced event rates, residual risk persists in many individuals. Contemporary research underscores the importance of tailoring preventive interventions to the individual, capitalizing on advances in genomics, molecular biomarkers, and digital health to optimize outcomes. Personalized prevention, also referred to as precision medicine, aims to refine risk prediction and therapeutic decision-making based on a comprehensive assessment of genetic, clinical, and lifestyle factors.

Epidemiology / Disease Burden

Globally, ischemic heart disease and stroke rank as the first and second leading causes of death, accounting for more than 17 million deaths annually. Despite improvements in acute care, the absolute number of events continues to rise due to aging populations and increasing prevalence of modifiable risk factors such as obesity, diabetes, and hypertension. Epidemiological studies reveal significant inter-individual variability in risk, underscoring the need for more nuanced preventive strategies that move beyond population averages.

Pathophysiology

The pathogenesis of heart attacks and strokes is multifactorial, involving a complex interplay between genetic susceptibility, endothelial dysfunction, atherogenesis, inflammation, and thrombosis. Recent advances in omics technologies have illuminated the molecular underpinnings of atherosclerosis and plaque instability, including the roles of lipid metabolism, immune modulation, and novel pathways such as clonal hematopoiesis. Understanding these mechanisms provides a foundation for the identification of new risk markers and therapeutic targets amenable to personalized intervention.

Risk Factors

Classic risk factors for cardiovascular and cerebrovascular disease include hypertension, dyslipidemia, diabetes, smoking, and sedentary lifestyle. However, individual risk is also shaped by non-traditional factors such as family history, ethnicity, psychosocial stress, and emerging biomarkers (e.g., high-sensitivity C-reactive protein, Lp(a), coronary artery calcium score). Polygenic risk scores, derived from genome-wide association studies, further refine risk stratification by capturing the cumulative impact of multiple genetic variants. Personalized risk assessment considers the aggregate of these factors to guide preventive strategies.

Clinical Features

While heart attacks typically present with chest pain, dyspnea, and diaphoresis, and strokes with focal neurological deficits, subclinical disease often precedes overt events by years or decades. Imaging modalities such as coronary computed tomography angiography and carotid ultrasound can detect subclinical atherosclerosis, facilitating earlier intervention in high-risk individuals. Recognizing clinical heterogeneity, including atypical presentations in women and older adults, is critical for timely diagnosis and prevention.

Diagnosis

Personalized prevention relies on accurate risk assessment using validated tools such as the ASCVD Pooled Cohort Equations, SCORE2, or the Framingham Risk Score, supplemented by biomarkers and imaging where appropriate. Genotyping for familial hypercholesterolemia or polygenic risk assessment may be indicated in select populations. Digital health platforms and wearable technologies are emerging as adjuncts for continuous monitoring and dynamic risk stratification, enabling more responsive preventive care.

Treatment & Management

Traditional management focuses on pharmacological control of blood pressure, cholesterol, and glucose, alongside lifestyle modification. Personalized prevention adapts these interventions to the individual risk profile. For example, statin therapy may be prioritized in patients with high coronary calcium scores or elevated Lp(a), while antihypertensive selection can be informed by pharmacogenomic data. Behavioral interventions such as tailored dietary and exercise plans are increasingly supported by digital health tools that account for cultural, socioeconomic, and psychological factors.

Recent Advances / Emerging Therapies

Recent years have witnessed notable advances in personalized cardiovascular prevention. The use of PCSK9 inhibitors, inclisiran, and bempedoic acid allows for individualized lipid-lowering strategies in statin-intolerant or high-risk patients. Anti-inflammatory agents such as canakinumab have demonstrated benefit in selected populations with residual inflammatory risk. Polygenic risk scores and multi-omics profiling are being integrated into clinical trials to further individualize prevention. Digital interventions, including mobile apps for medication adherence and AI-driven risk calculators, offer new avenues for enhancing preventive care at scale.

Guideline Recommendations

Major cardiovascular societies now endorse a personalized approach to prevention. The 2019 ESC/EAS guidelines advocate for risk-adapted intensity of preventive interventions and consideration of novel risk markers in ambiguous cases. The 2018 ACC/AHA guidelines recommend the use of coronary artery calcium scoring to refine statin eligibility in intermediate-risk individuals. Both emphasize shared decision-making, patient preferences, and the integration of genetic and biomarker data where evidence supports clinical utility.

Conclusion

Personalized prevention of heart attacks and stroke represents a paradigm shift in clinical practice, integrating advances in genomics, biomarkers, and digital health to improve risk prediction and guide therapy. While challenges remain in implementation and access, the promise of precision medicine lies in its potential to reduce the global burden of cardiovascular disease through more effective, individualized preventive strategies. Ongoing research and evolving guidelines will continue to shape the landscape of personalized cardiovascular prevention in the years to come.